novo nordisk semaglutide patent expires next year: faces tough competition in the Chinese obesity market Novo Nordisk and Mylan Settle

Most people lose 12 pounds per week on semaglutide, with total weight loss ranging from 1522% of body weight over 68 weeks in clinical trials

Does the use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) agonists have clinically significant effects on residual gastric volume (RGV) in the periprocedural period

Enhanced mitochondrial function and cellular energy production

by Sindhura Kolli, MD

Supported by NZD $30 million of funding and over ten years of research by the New Zealand Institute for Plant and Food Research Limited, a New Zealand government-owned Crown Research Institute